The liver has spent years as the quiet chapter of the GLP-1 story. Hearts and waistlines took the headlines, while people with fat in their liver followed biopsy trials from a distance and waited. That wait has ended in one specific sense: the Wegovy injection now carries an indication for a liver condition, the first liver indication any medicine in this class has received.
What follows reads the label and the trial behind it in plain English: what the condition is, what the indication covers and what it deliberately does not, how the result was measured in tissue rather than in symptoms, and what the accelerated approval pathway means for how much weight the indication can bear. One sentence frames all of it: no group average describes the liver of the person reading this.
Two words for one family of liver trouble
The vocabulary starts with MASLD, metabolic dysfunction-associated steatotic liver disease, which was formerly called nonalcoholic fatty liver disease. The name describes fat stored inside liver cells in the setting of metabolic disease, such as obesity or type 2 diabetes. The companion word, MASH, metabolic dysfunction-associated steatohepatitis, formerly nonalcoholic steatohepatitis or NASH, names the stage at which the fat is joined by inflammation and injury to liver cells.
The liver answers repeated injury the way other tissue does, by laying down scar material, and clinicians grade that scarring, called fibrosis, in stages. The indication and the trial behind it are built around those stages, and the boundaries matter enough that they get their own section below.
One more thing belongs here, because everything else depends on it: MASH is usually silent. It does not announce itself in a way a person could feel and report. Finding it, and grading it, takes a liver biopsy or imaging and blood based tests that a clinician orders and interprets. How any reader's own liver is doing is therefore not a question an article can answer, and this one will not try.
What the label actually says
The prescribing information states that Wegovy injection is indicated, in combination with a reduced calorie diet and increased physical activity, for the treatment of noncirrhotic MASH, formerly known as NASH, with moderate to advanced liver fibrosis, consistent with stages F2 to F3, in adults. Wegovy keeps its other two indications, reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and reducing excess body weight and maintaining that reduction. The liver indication is the second time a weight-loss GLP-1 has earned an approved use beyond weight itself, a path the heart outcome trials opened first, as covered in GLP-1s and the Heart: What the Outcome Trials Showed.
Two boundaries in that sentence do heavy work. The disease must be noncirrhotic, and the fibrosis must fall in the moderate to advanced range, F2 to F3. And the indication belongs to the injection, full stop. The Wegovy label now also covers tablets, but the tablet indications are cardiovascular risk reduction and weight reduction only. Anyone who reads a headline about Wegovy and the liver and concludes that the pill carries the same indication has misread the label.
It is also worth saying plainly that this indication is Wegovy injection's alone. As of this writing, no other GLP-1 medicine carries a liver indication, and the absence of one on another label is a statement about trials run and reviewed, not a statement about biology.
A trial measured in tissue, not symptoms
The indication rests on a 240 week, randomized, double blind, placebo controlled trial, registered as NCT04822181, with the analysis supporting approval taken at week 72. Entering the trial required a liver biopsy showing MASH with fibrosis stage 2 or 3. The week 72 analysis included 800 patients, 266 randomized to placebo and 534 to semaglutide. Their livers sat squarely in the middle of the scarring range: 250 patients, 31 percent, had F2 fibrosis, and 550, 69 percent, had F3. The group carried substantial cardiometabolic disease, with 56 percent having type 2 diabetes, a median age of 57, 57 percent female, and a median BMI of 34. The dose was escalated to 2.4 mg once weekly over the first 16 weeks.
Nothing in that design is decoration. The outcomes were read from liver biopsies, and each biopsy was read by two pathologists independently, with a third adjudicating disagreements. What the trial measured was change under the microscope: whether the inflammation resolved, whether the scarring improved, and crucially whether one happened without worsening the other.
The week 72 results, semaglutide versus placebo: 63 percent versus 34 percent achieved resolution of steatohepatitis with no worsening of fibrosis, a difference of 29 percentage points with a 95 percent confidence interval of 21 to 36. For improvement in liver fibrosis with no worsening of steatohepatitis, the figures were 37 percent versus 22 percent, a 14 point difference with a confidence interval of 8 to 21. For both together, resolution and fibrosis improvement, 33 percent versus 16 percent, a 17 point difference with a confidence interval of 10 to 23.
The placebo arm improved too
The single most misread number in that list is the placebo group's 34 percent. A third of the people who received no active medicine showed biopsy resolution of their steatohepatitis. Nobody in this trial sat untreated: everyone received standard care for their cardiometabolic conditions plus healthy lifestyle counseling, and the design gave both arms that same foundation.
That is why the drug effect is the difference between the arms, 29 percentage points on the primary tissue outcome, and not the whole 63 percent in the treatment arm. Reading the 63 without the 34 credits the medicine with everything the trial's shared care accomplished, and that mistake is how trial results get inflated in headlines across all of medicine.
GLP 1 Tracker AppEvery dose dated, side effects noted, weight trend kept: a record that makes the appointments around a treatment plan shorter and sharper.
Get the app
What accelerated approval buys, and what it owes
The label says it in its own words: the indication is approved under accelerated approval based on improvement of MASH and fibrosis, and continued approval may be contingent upon the verification and description of clinical benefit in a confirmatory trial. Unpacked, the FDA accepted a change in biopsy tissue as a stand-in for the outcomes that matter most to a person with this disease, progression to cirrhosis, liver failure and death. Waiting to count those events takes many years, so the pathway trades speed now for a debt later: the 240 week trial is still running to confirm that the tissue changes predict real clinical benefit, and if the confirmatory data disappoint, the indication can be withdrawn.
There is nothing backroom about this. It is a deliberate, public trade, used across medicine for serious diseases where the endpoint that matters takes too long to reach. It does mean the indication rests on a different kind of evidence than a completed outcome trial provides, and readers deserve to know which kind they are looking at.
The boundary the label draws
Noncirrhotic and F2 to F3 are boundaries, not decoration. The trial did not enroll people with cirrhosis, stage F4, so the label does not cover them, and nothing in the trial speaks to disease that far advanced. The same honesty applies at the other end of the question: a person cannot know their own fibrosis stage from how they feel, because the disease is usually silent, and staging comes from a biopsy or from imaging and blood based tests a clinician orders and interprets.
Liver values do come up in ordinary monitoring on these medicines, and what any of those numbers means belongs entirely to the clinician who ordered them; for that wider subject, see Blood Work on a GLP-1: Numbers Worth Keeping. The kidney story followed a similar pattern of a named population and a counted outcome before it reached a label, as covered in GLP-1s and Your Kidneys: Why Dehydration Is the Risk.
Which leaves the finding itself, stated honestly: in a group of 800 adults with biopsy-confirmed MASH and F2 to F3 fibrosis, semaglutide improved tissue outcomes more than placebo did at 72 weeks, against a backdrop where a third of the placebo group improved too, and the trial continues to test what that improvement means for the long run. That is a genuinely notable result, and it is a group result. Translating it into anything about an individual liver is a job for the clinicians who can see the biopsy, the history and everything else, never for an article.
Frequently asked questions
Is Wegovy approved for fatty liver?
Wegovy injection is indicated, in combination with a reduced calorie diet and increased physical activity, for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis, stages F2 to F3, in adults. It is the first liver indication any GLP-1 medicine has carried. The approval came under the accelerated pathway based on improvement of MASH and fibrosis, with a confirmatory trial still required. The Wegovy tablet does not carry this indication.
What is the difference between MASLD and MASH?
MASLD, metabolic dysfunction-associated steatotic liver disease, formerly called nonalcoholic fatty liver disease, describes fat stored in liver cells in the setting of metabolic disease. MASH, formerly nonalcoholic steatohepatitis or NASH, is the stage where that fat is joined by inflammation and injury to liver cells. Both are usually silent, and grading them takes a biopsy or imaging and blood based tests that a clinician orders and interprets.
What did the semaglutide MASH trial actually show?
At week 72 of a 240 week trial, 800 adults with biopsy-confirmed MASH and stage 2 or 3 fibrosis were compared: 63 percent on semaglutide versus 34 percent on placebo achieved resolution of steatohepatitis with no worsening of fibrosis, and 37 percent versus 22 percent improved fibrosis with no worsening of steatohepatitis. Every outcome was read from liver biopsies by two pathologists, with a third adjudicating disagreements. These are group results, measured in tissue at one time point.
Do Ozempic or Mounjaro have a liver indication too?
As of this writing, the MASH indication belongs to Wegovy injection alone. An indication reflects the trials a company ran and the FDA reviewed, so its absence on another label means that use has not been approved on that evidence, not that the medicine has been tested and failed. Reading the label of one product as a statement about another is exactly the comparison a label cannot support.
What does accelerated approval mean for a liver drug?
It means the FDA accepted a change in biopsy tissue as a stand-in for the outcomes that matter most, progression to cirrhosis, liver failure and death, because waiting to count those events takes many years. The trade is explicit: the indication is granted now, and continued approval may be contingent on a confirmatory trial verifying the clinical benefit. If the confirmatory data disappoint, the indication can be withdrawn.